Wednesday, October 26, 2016

Most Accessed Article: AAV Vectorization of DSB-mediated Gene Editing Technologies

AAV Vectorization of DSB-mediated Gene Editing Technologies

Rachel J. Moser and Matthew L. HirschPages 207-219 (13)


Recent work both at the bench and the bedside demonstrate zinc-finger nucleases (ZFNs), CRISPR/Cas9, and other programmable site-specific endonuclease technologies are being successfully utilized within and alongside AAV vectors to induce therapeutically relevant levels of directed gene editing within the human chromosome. Studies from past decades acknowledge that AAV vector genomes are enhanced substrates for homology-directed repair in the presence or absence of targeted DNA damage within the host genome. Additionally, AAV vectors are currently the most efficient format for in vivo gene delivery with no vector related complications in >100 clinical trials for diverse diseases. At the same time, advancements in the design of custom-engineered site-specific endonucleases and the utilization of elucidated endonuclease formats have resulted in efficient and facile genetic engineering for basic science and for clinical therapies. AAV vectors and gene editing technologies are an obvious marriage, using AAV for the delivery of repair substrate and/or a gene encoding a designer endonuclease; however, while efficient delivery and enhanced gene targeting by vector genomes are advantageous, other attributes of AAV vectors are less desirable for gene editing technologies. This review summarizes the various roles that AAV vectors play in gene editing technologies and provides insight into its trending applications for the treatment of genetic diseases.


AAV Vectorization, DSB, CRISPR/Cas9, DNA, ZFNs.

Department of Ophthalmology, Gene Therapy Center, University of North Carolina at Chapel Hill, Campus Box 7352, Chapel Hill, NC 27599-7352, USA.

For More Information Please Visit Our Website Current Gene Therapy



Post a Comment